nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—MAPK8—stomach cancer	0.255	0.551	CbGaD
Nilotinib—CA1—stomach cancer	0.118	0.256	CbGaD
Nilotinib—CA2—stomach cancer	0.0895	0.194	CbGaD
Nilotinib—UGT1A1—Irinotecan—stomach cancer	0.0284	0.162	CbGbCtD
Nilotinib—ABCB1—Mitomycin—stomach cancer	0.0219	0.125	CbGbCtD
Nilotinib—ABCG2—Irinotecan—stomach cancer	0.0156	0.089	CbGbCtD
Nilotinib—ABCG2—Fluorouracil—stomach cancer	0.015	0.0854	CbGbCtD
Nilotinib—ABCG2—Docetaxel—stomach cancer	0.0114	0.0652	CbGbCtD
Nilotinib—CYP2B6—Irinotecan—stomach cancer	0.011	0.0626	CbGbCtD
Nilotinib—CYP2C9—Capecitabine—stomach cancer	0.00939	0.0535	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—stomach cancer	0.00853	0.0486	CbGbCtD
Nilotinib—ABCG2—Methotrexate—stomach cancer	0.00826	0.0471	CbGbCtD
Nilotinib—CYP2C8—Fluorouracil—stomach cancer	0.00798	0.0455	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—stomach cancer	0.006	0.0342	CbGbCtD
Nilotinib—ABCB1—Irinotecan—stomach cancer	0.00563	0.0321	CbGbCtD
Nilotinib—CYP2C9—Fluorouracil—stomach cancer	0.00557	0.0317	CbGbCtD
Nilotinib—ABCB1—Docetaxel—stomach cancer	0.00412	0.0235	CbGbCtD
Nilotinib—CYP3A4—Irinotecan—stomach cancer	0.00337	0.0192	CbGbCtD
Nilotinib—ABCB1—Doxorubicin—stomach cancer	0.00307	0.0175	CbGbCtD
Nilotinib—KIT—myenteric nerve plexus—stomach cancer	0.00305	0.0383	CbGeAlD
Nilotinib—ABCB1—Methotrexate—stomach cancer	0.00298	0.017	CbGbCtD
Nilotinib—CYP2D6—Doxorubicin—stomach cancer	0.0029	0.0165	CbGbCtD
Nilotinib—CYP3A4—Docetaxel—stomach cancer	0.00247	0.0141	CbGbCtD
Nilotinib—CYP3A4—Doxorubicin—stomach cancer	0.00184	0.0105	CbGbCtD
Nilotinib—Ponatinib—FGFR2—stomach cancer	0.00179	0.561	CrCbGaD
Nilotinib—MAPK8—blood vessel—stomach cancer	0.00149	0.0188	CbGeAlD
Nilotinib—TIE1—blood vessel—stomach cancer	0.00129	0.0163	CbGeAlD
Nilotinib—FRK—hematopoietic system—stomach cancer	0.00104	0.0131	CbGeAlD
Nilotinib—BLK—hematopoietic system—stomach cancer	0.00101	0.0127	CbGeAlD
Nilotinib—EPHB2—hematopoietic system—stomach cancer	0.000995	0.0125	CbGeAlD
Nilotinib—ABL1—Topotecan—Irinotecan—stomach cancer	0.00097	0.424	CbGdCrCtD
Nilotinib—MAPK14—blood vessel—stomach cancer	0.000948	0.0119	CbGeAlD
Nilotinib—CA9—gall bladder—stomach cancer	0.000915	0.0115	CbGeAlD
Nilotinib—EPHB4—blood vessel—stomach cancer	0.000899	0.0113	CbGeAlD
Nilotinib—EPHA2—blood vessel—stomach cancer	0.000882	0.0111	CbGeAlD
Nilotinib—TEK—blood vessel—stomach cancer	0.00086	0.0108	CbGeAlD
Nilotinib—MAPK8—hematopoietic system—stomach cancer	0.000795	0.01	CbGeAlD
Nilotinib—CDC42BPB—smooth muscle tissue—stomach cancer	0.000774	0.00974	CbGeAlD
Nilotinib—FRK—lymphoid tissue—stomach cancer	0.000734	0.00923	CbGeAlD
Nilotinib—LYN—hematopoietic system—stomach cancer	0.000734	0.00923	CbGeAlD
Nilotinib—PDGFRA—gall bladder—stomach cancer	0.000733	0.00923	CbGeAlD
Nilotinib—MAPK8—epithelium—stomach cancer	0.000727	0.00914	CbGeAlD
Nilotinib—MAP4K1—hematopoietic system—stomach cancer	0.000723	0.00909	CbGeAlD
Nilotinib—Imatinib—CA1—stomach cancer	0.00071	0.223	CrCbGaD
Nilotinib—BLK—lymphoid tissue—stomach cancer	0.000708	0.00891	CbGeAlD
Nilotinib—MAPK8—smooth muscle tissue—stomach cancer	0.0007	0.00881	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—stomach cancer	0.0007	0.00881	CbGeAlD
Nilotinib—EPHB2—digestive system—stomach cancer	0.000692	0.0087	CbGeAlD
Nilotinib—TIE1—hematopoietic system—stomach cancer	0.000689	0.00867	CbGeAlD
Nilotinib—MAPK8—pancreas—stomach cancer	0.000647	0.00814	CbGeAlD
Nilotinib—TIE1—epithelium—stomach cancer	0.00063	0.00793	CbGeAlD
Nilotinib—KIT—blood vessel—stomach cancer	0.000623	0.00784	CbGeAlD
Nilotinib—CDC42BPB—digestive system—stomach cancer	0.000611	0.00769	CbGeAlD
Nilotinib—PDGFRB—blood vessel—stomach cancer	0.000609	0.00766	CbGeAlD
Nilotinib—TIE1—smooth muscle tissue—stomach cancer	0.000607	0.00764	CbGeAlD
Nilotinib—HCK—hematopoietic system—stomach cancer	0.000603	0.00758	CbGeAlD
Nilotinib—FRK—endocrine gland—stomach cancer	0.000599	0.00754	CbGeAlD
Nilotinib—KIT—gall bladder—stomach cancer	0.000586	0.00738	CbGeAlD
Nilotinib—PDGFRB—gall bladder—stomach cancer	0.000573	0.0072	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—stomach cancer	0.00056	0.00704	CbGeAlD
Nilotinib—MAPK8—digestive system—stomach cancer	0.000553	0.00696	CbGeAlD
Nilotinib—FRK—liver—stomach cancer	0.00054	0.00679	CbGeAlD
Nilotinib—Imatinib—CA2—stomach cancer	0.000538	0.169	CrCbGaD
Nilotinib—LYN—lymphoid tissue—stomach cancer	0.000517	0.0065	CbGeAlD
Nilotinib—MAPK8—bone marrow—stomach cancer	0.00051	0.00641	CbGeAlD
Nilotinib—MAP4K1—lymphoid tissue—stomach cancer	0.000509	0.0064	CbGeAlD
Nilotinib—CDC42BPB—endocrine gland—stomach cancer	0.000505	0.00636	CbGeAlD
Nilotinib—MAPK14—hematopoietic system—stomach cancer	0.000505	0.00635	CbGeAlD
Nilotinib—FGR—hematopoietic system—stomach cancer	0.000503	0.00633	CbGeAlD
Nilotinib—EPHB4—hematopoietic system—stomach cancer	0.000479	0.00602	CbGeAlD
Nilotinib—EPHA2—hematopoietic system—stomach cancer	0.00047	0.00591	CbGeAlD
Nilotinib—MAP4K1—bone marrow—stomach cancer	0.000463	0.00583	CbGeAlD
Nilotinib—MAPK14—epithelium—stomach cancer	0.000462	0.00581	CbGeAlD
Nilotinib—TEK—hematopoietic system—stomach cancer	0.000458	0.00576	CbGeAlD
Nilotinib—MAPK8—endocrine gland—stomach cancer	0.000457	0.00575	CbGeAlD
Nilotinib—EPHA6—endocrine gland—stomach cancer	0.000457	0.00575	CbGeAlD
Nilotinib—EPHB3—digestive system—stomach cancer	0.000456	0.00574	CbGeAlD
Nilotinib—CDC42BPB—liver—stomach cancer	0.000455	0.00573	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—stomach cancer	0.000445	0.00559	CbGeAlD
Nilotinib—EPHB4—epithelium—stomach cancer	0.000438	0.0055	CbGeAlD
Nilotinib—EPHA2—epithelium—stomach cancer	0.000429	0.0054	CbGeAlD
Nilotinib—HCK—lymphoid tissue—stomach cancer	0.000424	0.00534	CbGeAlD
Nilotinib—BRAF—bone marrow—stomach cancer	0.000424	0.00533	CbGeAlD
Nilotinib—LYN—endocrine gland—stomach cancer	0.000422	0.0053	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—stomach cancer	0.000422	0.0053	CbGeAlD
Nilotinib—HCK—digestive system—stomach cancer	0.000419	0.00527	CbGeAlD
Nilotinib—TEK—epithelium—stomach cancer	0.000419	0.00527	CbGeAlD
Nilotinib—PDGFRA—hematopoietic system—stomach cancer	0.000415	0.00522	CbGeAlD
Nilotinib—MAPK8—liver—stomach cancer	0.000412	0.00518	CbGeAlD
Nilotinib—CA7—digestive system—stomach cancer	0.00041	0.00516	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—stomach cancer	0.000403	0.00508	CbGeAlD
Nilotinib—BLK—lymph node—stomach cancer	0.0004	0.00503	CbGeAlD
Nilotinib—UGT1A1—hematopoietic system—stomach cancer	0.000396	0.00498	CbGeAlD
Nilotinib—EPHB4—pancreas—stomach cancer	0.00039	0.0049	CbGeAlD
Nilotinib—HCK—bone marrow—stomach cancer	0.000386	0.00486	CbGeAlD
Nilotinib—EPHA2—pancreas—stomach cancer	0.000382	0.00481	CbGeAlD
Nilotinib—LYN—liver—stomach cancer	0.00038	0.00478	CbGeAlD
Nilotinib—TEK—pancreas—stomach cancer	0.000373	0.00469	CbGeAlD
Nilotinib—PDGFRA—smooth muscle tissue—stomach cancer	0.000366	0.0046	CbGeAlD
Nilotinib—CSF1R—hematopoietic system—stomach cancer	0.000365	0.0046	CbGeAlD
Nilotinib—CA9—digestive system—stomach cancer	0.00036	0.00453	CbGeAlD
Nilotinib—TIE1—liver—stomach cancer	0.000357	0.00449	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—stomach cancer	0.000355	0.00447	CbGeAlD
Nilotinib—FGR—lymphoid tissue—stomach cancer	0.000354	0.00445	CbGeAlD
Nilotinib—MAPK11—lymph node—stomach cancer	0.000352	0.00443	CbGeAlD
Nilotinib—MAPK14—digestive system—stomach cancer	0.000351	0.00442	CbGeAlD
Nilotinib—FGR—digestive system—stomach cancer	0.00035	0.0044	CbGeAlD
Nilotinib—CDC42BPB—lymph node—stomach cancer	0.000349	0.00439	CbGeAlD
Nilotinib—CA2—gall bladder—stomach cancer	0.000348	0.00437	CbGeAlD
Nilotinib—CA3—bone marrow—stomach cancer	0.000347	0.00436	CbGeAlD
Nilotinib—HCK—endocrine gland—stomach cancer	0.000346	0.00436	CbGeAlD
Nilotinib—BRAF—liver—stomach cancer	0.000342	0.00431	CbGeAlD
Nilotinib—EPHB4—digestive system—stomach cancer	0.000333	0.00419	CbGeAlD
Nilotinib—KIT—hematopoietic system—stomach cancer	0.000332	0.00417	CbGeAlD
Nilotinib—EPHA3—lymph node—stomach cancer	0.000331	0.00416	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—stomach cancer	0.000331	0.00416	CbGeAlD
Nilotinib—EPHA2—digestive system—stomach cancer	0.000327	0.00411	CbGeAlD
Nilotinib—PDGFRB—hematopoietic system—stomach cancer	0.000324	0.00408	CbGeAlD
Nilotinib—MAPK14—bone marrow—stomach cancer	0.000324	0.00407	CbGeAlD
Nilotinib—TEK—lymphoid tissue—stomach cancer	0.000323	0.00406	CbGeAlD
Nilotinib—LCK—bone marrow—stomach cancer	0.000322	0.00406	CbGeAlD
Nilotinib—FGR—bone marrow—stomach cancer	0.000322	0.00406	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—stomach cancer	0.000322	0.00405	CbGeAlD
Nilotinib—MAPK8—lymph node—stomach cancer	0.000316	0.00397	CbGeAlD
Nilotinib—EPHA4—endocrine gland—stomach cancer	0.000315	0.00396	CbGeAlD
Nilotinib—HCK—liver—stomach cancer	0.000312	0.00393	CbGeAlD
Nilotinib—CA3—endocrine gland—stomach cancer	0.000311	0.00391	CbGeAlD
Nilotinib—ABL2—liver—stomach cancer	0.00031	0.0039	CbGeAlD
Nilotinib—EPHB4—bone marrow—stomach cancer	0.000307	0.00386	CbGeAlD
Nilotinib—CA1—hematopoietic system—stomach cancer	0.000303	0.00382	CbGeAlD
Nilotinib—KIT—epithelium—stomach cancer	0.000303	0.00382	CbGeAlD
Nilotinib—CA9—endocrine gland—stomach cancer	0.000298	0.00374	CbGeAlD
Nilotinib—PDGFRB—epithelium—stomach cancer	0.000296	0.00373	CbGeAlD
Nilotinib—KIT—smooth muscle tissue—stomach cancer	0.000292	0.00368	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—stomach cancer	0.000292	0.00368	CbGeAlD
Nilotinib—MAPK14—endocrine gland—stomach cancer	0.00029	0.00365	CbGeAlD
Nilotinib—FGR—endocrine gland—stomach cancer	0.000289	0.00364	CbGeAlD
Nilotinib—ABL1—hematopoietic system—stomach cancer	0.000289	0.00363	CbGeAlD
Nilotinib—PDGFRA—digestive system—stomach cancer	0.000289	0.00363	CbGeAlD
Nilotinib—MAP4K1—lymph node—stomach cancer	0.000287	0.00361	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—stomach cancer	0.000285	0.00359	CbGeAlD
Nilotinib—CA3—liver—stomach cancer	0.00028	0.00353	CbGeAlD
Nilotinib—UGT1A1—digestive system—stomach cancer	0.000275	0.00346	CbGeAlD
Nilotinib—EPHB4—endocrine gland—stomach cancer	0.000275	0.00346	CbGeAlD
Nilotinib—TIE1—lymph node—stomach cancer	0.000274	0.00344	CbGeAlD
Nilotinib—KIT—pancreas—stomach cancer	0.00027	0.0034	CbGeAlD
Nilotinib—EPHA2—endocrine gland—stomach cancer	0.00027	0.00339	CbGeAlD
Nilotinib—CA12—digestive system—stomach cancer	0.000266	0.00335	CbGeAlD
Nilotinib—PDGFRB—pancreas—stomach cancer	0.000264	0.00332	CbGeAlD
Nilotinib—TEK—endocrine gland—stomach cancer	0.000263	0.00331	CbGeAlD
Nilotinib—BRAF—lymph node—stomach cancer	0.000263	0.0033	CbGeAlD
Nilotinib—MAPK14—liver—stomach cancer	0.000262	0.00329	CbGeAlD
Nilotinib—LCK—liver—stomach cancer	0.000261	0.00328	CbGeAlD
Nilotinib—FGR—liver—stomach cancer	0.000261	0.00328	CbGeAlD
Nilotinib—EPHB3—lymph node—stomach cancer	0.00026	0.00328	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—stomach cancer	0.000257	0.00324	CbGeAlD
Nilotinib—CA14—liver—stomach cancer	0.000254	0.0032	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—stomach cancer	0.000254	0.0032	CbGeAlD
Nilotinib—CSF1R—digestive system—stomach cancer	0.000254	0.0032	CbGeAlD
Nilotinib—EPHB4—liver—stomach cancer	0.000248	0.00312	CbGeAlD
Nilotinib—CA1—pancreas—stomach cancer	0.000247	0.00311	CbGeAlD
Nilotinib—EPHA2—liver—stomach cancer	0.000243	0.00306	CbGeAlD
Nilotinib—HCK—lymph node—stomach cancer	0.000239	0.00301	CbGeAlD
Nilotinib—PDGFRA—endocrine gland—stomach cancer	0.000238	0.003	CbGeAlD
Nilotinib—ABL2—lymph node—stomach cancer	0.000238	0.00299	CbGeAlD
Nilotinib—TEK—liver—stomach cancer	0.000237	0.00299	CbGeAlD
Nilotinib—ABL1—pancreas—stomach cancer	0.000235	0.00296	CbGeAlD
Nilotinib—CSF1R—bone marrow—stomach cancer	0.000234	0.00295	CbGeAlD
Nilotinib—KIT—lymphoid tissue—stomach cancer	0.000234	0.00294	CbGeAlD
Nilotinib—KIT—digestive system—stomach cancer	0.000231	0.0029	CbGeAlD
Nilotinib—PDGFRB—lymphoid tissue—stomach cancer	0.000228	0.00287	CbGeAlD
Nilotinib—ABL1—Doxorubicin—Epirubicin—stomach cancer	0.000228	0.0997	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Epirubicin—stomach cancer	0.000228	0.0997	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Epirubicin—stomach cancer	0.000228	0.0997	CbGdCrCtD
Nilotinib—UGT1A1—endocrine gland—stomach cancer	0.000228	0.00286	CbGeAlD
Nilotinib—PDGFRB—digestive system—stomach cancer	0.000225	0.00284	CbGeAlD
Nilotinib—CA12—endocrine gland—stomach cancer	0.00022	0.00277	CbGeAlD
Nilotinib—EPHA4—lymph node—stomach cancer	0.000218	0.00274	CbGeAlD
Nilotinib—MAP2K5—endocrine gland—stomach cancer	0.000215	0.00271	CbGeAlD
Nilotinib—PDGFRA—liver—stomach cancer	0.000215	0.00271	CbGeAlD
Nilotinib—CA3—lymph node—stomach cancer	0.000215	0.0027	CbGeAlD
Nilotinib—CA1—lymphoid tissue—stomach cancer	0.000214	0.00269	CbGeAlD
Nilotinib—KIT—bone marrow—stomach cancer	0.000213	0.00268	CbGeAlD
Nilotinib—CA1—digestive system—stomach cancer	0.000211	0.00265	CbGeAlD
Nilotinib—ABL1—Idarubicin—Doxorubicin—stomach cancer	0.000211	0.0923	CbGdCrCtD
Nilotinib—ABL1—Epirubicin—Doxorubicin—stomach cancer	0.000211	0.0923	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—stomach cancer	0.000211	0.0923	CbGdCrCtD
Nilotinib—CSF1R—endocrine gland—stomach cancer	0.00021	0.00264	CbGeAlD
Nilotinib—PDGFRB—bone marrow—stomach cancer	0.000208	0.00261	CbGeAlD
Nilotinib—UGT1A1—liver—stomach cancer	0.000205	0.00258	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—stomach cancer	0.000203	0.00256	CbGeAlD
Nilotinib—ABL1—digestive system—stomach cancer	0.000201	0.00253	CbGeAlD
Nilotinib—MAPK14—lymph node—stomach cancer	0.000201	0.00252	CbGeAlD
Nilotinib—LCK—lymph node—stomach cancer	0.0002	0.00251	CbGeAlD
Nilotinib—FGR—lymph node—stomach cancer	0.0002	0.00251	CbGeAlD
Nilotinib—CA2—hematopoietic system—stomach cancer	0.000197	0.00247	CbGeAlD
Nilotinib—CA1—bone marrow—stomach cancer	0.000195	0.00245	CbGeAlD
Nilotinib—MAP2K5—liver—stomach cancer	0.000194	0.00244	CbGeAlD
Nilotinib—KIT—endocrine gland—stomach cancer	0.000191	0.0024	CbGeAlD
Nilotinib—EPHB4—lymph node—stomach cancer	0.00019	0.00239	CbGeAlD
Nilotinib—CSF1R—liver—stomach cancer	0.000189	0.00238	CbGeAlD
Nilotinib—CYP2C8—hematopoietic system—stomach cancer	0.000187	0.00236	CbGeAlD
Nilotinib—EPHA2—lymph node—stomach cancer	0.000187	0.00235	CbGeAlD
Nilotinib—PDGFRB—endocrine gland—stomach cancer	0.000186	0.00234	CbGeAlD
Nilotinib—ABL1—bone marrow—stomach cancer	0.000185	0.00233	CbGeAlD
Nilotinib—TEK—lymph node—stomach cancer	0.000182	0.00229	CbGeAlD
Nilotinib—CA2—epithelium—stomach cancer	0.00018	0.00226	CbGeAlD
Nilotinib—CA1—endocrine gland—stomach cancer	0.000174	0.00219	CbGeAlD
Nilotinib—EPHB6—lymph node—stomach cancer	0.000174	0.00219	CbGeAlD
Nilotinib—CA2—smooth muscle tissue—stomach cancer	0.000173	0.00218	CbGeAlD
Nilotinib—KIT—liver—stomach cancer	0.000172	0.00216	CbGeAlD
Nilotinib—ABCB1—blood vessel—stomach cancer	0.000169	0.00212	CbGeAlD
Nilotinib—CYP2B6—hematopoietic system—stomach cancer	0.000168	0.00211	CbGeAlD
Nilotinib—PDGFRB—liver—stomach cancer	0.000168	0.00211	CbGeAlD
Nilotinib—CYP2C9—hematopoietic system—stomach cancer	0.000166	0.00209	CbGeAlD
Nilotinib—ABL1—endocrine gland—stomach cancer	0.000166	0.00209	CbGeAlD
Nilotinib—CA4—digestive system—stomach cancer	0.000165	0.00208	CbGeAlD
Nilotinib—PDGFRA—lymph node—stomach cancer	0.000165	0.00207	CbGeAlD
Nilotinib—CA2—pancreas—stomach cancer	0.00016	0.00201	CbGeAlD
Nilotinib—CA1—liver—stomach cancer	0.000157	0.00198	CbGeAlD
Nilotinib—CA4—bone marrow—stomach cancer	0.000152	0.00191	CbGeAlD
Nilotinib—Imatinib—ALB—stomach cancer	0.00015	0.0472	CrCbGaD
Nilotinib—ABL1—liver—stomach cancer	0.00015	0.00188	CbGeAlD
Nilotinib—MAP2K5—lymph node—stomach cancer	0.000149	0.00187	CbGeAlD
Nilotinib—CSF1R—lymph node—stomach cancer	0.000145	0.00183	CbGeAlD
Nilotinib—CA2—lymphoid tissue—stomach cancer	0.000138	0.00174	CbGeAlD
Nilotinib—CA2—digestive system—stomach cancer	0.000137	0.00172	CbGeAlD
Nilotinib—CA4—endocrine gland—stomach cancer	0.000136	0.00171	CbGeAlD
Nilotinib—KIT—lymph node—stomach cancer	0.000132	0.00166	CbGeAlD
Nilotinib—PDGFRB—lymph node—stomach cancer	0.000129	0.00162	CbGeAlD
Nilotinib—CYP3A4—hematopoietic system—stomach cancer	0.000127	0.0016	CbGeAlD
Nilotinib—CA2—bone marrow—stomach cancer	0.000126	0.00159	CbGeAlD
Nilotinib—CYP2D6—hematopoietic system—stomach cancer	0.000125	0.00157	CbGeAlD
Nilotinib—CA1—lymph node—stomach cancer	0.000121	0.00152	CbGeAlD
Nilotinib—CYP2B6—lymphoid tissue—stomach cancer	0.000118	0.00149	CbGeAlD
Nilotinib—CYP2B6—digestive system—stomach cancer	0.000117	0.00147	CbGeAlD
Nilotinib—ABCG2—bone marrow—stomach cancer	0.000117	0.00147	CbGeAlD
Nilotinib—CYP2C9—digestive system—stomach cancer	0.000116	0.00146	CbGeAlD
Nilotinib—ABL1—lymph node—stomach cancer	0.000115	0.00144	CbGeAlD
Nilotinib—CA2—endocrine gland—stomach cancer	0.000113	0.00142	CbGeAlD
Nilotinib—CYP2C8—endocrine gland—stomach cancer	0.000108	0.00135	CbGeAlD
Nilotinib—CA2—liver—stomach cancer	0.000102	0.00128	CbGeAlD
Nilotinib—CYP2C8—liver—stomach cancer	9.71e-05	0.00122	CbGeAlD
Nilotinib—CYP2B6—endocrine gland—stomach cancer	9.66e-05	0.00121	CbGeAlD
Nilotinib—CYP2C9—endocrine gland—stomach cancer	9.56e-05	0.0012	CbGeAlD
Nilotinib—ABCG2—liver—stomach cancer	9.44e-05	0.00119	CbGeAlD
Nilotinib—CA4—lymph node—stomach cancer	9.42e-05	0.00119	CbGeAlD
Nilotinib—ABCB1—hematopoietic system—stomach cancer	8.98e-05	0.00113	CbGeAlD
Nilotinib—CYP3A4—digestive system—stomach cancer	8.82e-05	0.00111	CbGeAlD
Nilotinib—CYP2B6—liver—stomach cancer	8.71e-05	0.0011	CbGeAlD
Nilotinib—CYP2D6—digestive system—stomach cancer	8.68e-05	0.00109	CbGeAlD
Nilotinib—CYP2C9—liver—stomach cancer	8.62e-05	0.00108	CbGeAlD
Nilotinib—ABCB1—epithelium—stomach cancer	8.21e-05	0.00103	CbGeAlD
Nilotinib—CA2—lymph node—stomach cancer	7.81e-05	0.000983	CbGeAlD
Nilotinib—ABCB1—pancreas—stomach cancer	7.31e-05	0.00092	CbGeAlD
Nilotinib—CYP3A4—endocrine gland—stomach cancer	7.29e-05	0.000917	CbGeAlD
Nilotinib—ABCG2—lymph node—stomach cancer	7.24e-05	0.00091	CbGeAlD
Nilotinib—CYP2D6—endocrine gland—stomach cancer	7.17e-05	0.000903	CbGeAlD
Nilotinib—CYP3A4—liver—stomach cancer	6.57e-05	0.000827	CbGeAlD
Nilotinib—CYP2D6—liver—stomach cancer	6.47e-05	0.000814	CbGeAlD
Nilotinib—ABCB1—lymphoid tissue—stomach cancer	6.32e-05	0.000795	CbGeAlD
Nilotinib—ABCB1—digestive system—stomach cancer	6.25e-05	0.000786	CbGeAlD
Nilotinib—ABCB1—bone marrow—stomach cancer	5.76e-05	0.000724	CbGeAlD
Nilotinib—ABCB1—endocrine gland—stomach cancer	5.16e-05	0.000649	CbGeAlD
Nilotinib—ABCB1—liver—stomach cancer	4.65e-05	0.000585	CbGeAlD
Nilotinib—Erythema—Methotrexate—stomach cancer	4.42e-05	0.000359	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—stomach cancer	4.41e-05	0.000359	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Capecitabine—stomach cancer	4.41e-05	0.000358	CcSEcCtD
Nilotinib—Flushing—Epirubicin—stomach cancer	4.41e-05	0.000358	CcSEcCtD
Nilotinib—Cardiac disorder—Epirubicin—stomach cancer	4.41e-05	0.000358	CcSEcCtD
Nilotinib—Vomiting—Fluorouracil—stomach cancer	4.4e-05	0.000358	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—stomach cancer	4.4e-05	0.000358	CcSEcCtD
Nilotinib—Dyspepsia—Docetaxel—stomach cancer	4.4e-05	0.000358	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—stomach cancer	4.39e-05	0.000357	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—stomach cancer	4.39e-05	0.000357	CcSEcCtD
Nilotinib—Insomnia—Capecitabine—stomach cancer	4.38e-05	0.000356	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—stomach cancer	4.37e-05	0.000355	CcSEcCtD
Nilotinib—Rash—Fluorouracil—stomach cancer	4.37e-05	0.000355	CcSEcCtD
Nilotinib—Dermatitis—Fluorouracil—stomach cancer	4.36e-05	0.000355	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—stomach cancer	4.36e-05	0.000354	CcSEcCtD
Nilotinib—Paraesthesia—Capecitabine—stomach cancer	4.35e-05	0.000353	CcSEcCtD
Nilotinib—Decreased appetite—Docetaxel—stomach cancer	4.35e-05	0.000353	CcSEcCtD
Nilotinib—Headache—Fluorouracil—stomach cancer	4.34e-05	0.000353	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—stomach cancer	4.34e-05	0.000353	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—stomach cancer	4.33e-05	0.000352	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—stomach cancer	4.32e-05	0.000351	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Docetaxel—stomach cancer	4.32e-05	0.000351	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—stomach cancer	4.32e-05	0.000351	CcSEcCtD
Nilotinib—Dyspnoea—Capecitabine—stomach cancer	4.32e-05	0.000351	CcSEcCtD
Nilotinib—Fatigue—Docetaxel—stomach cancer	4.31e-05	0.00035	CcSEcCtD
Nilotinib—Angiopathy—Epirubicin—stomach cancer	4.31e-05	0.00035	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—stomach cancer	4.31e-05	0.00035	CcSEcCtD
Nilotinib—Nausea—Irinotecan—stomach cancer	4.3e-05	0.000349	CcSEcCtD
Nilotinib—Immune system disorder—Epirubicin—stomach cancer	4.29e-05	0.000348	CcSEcCtD
Nilotinib—Mediastinal disorder—Epirubicin—stomach cancer	4.28e-05	0.000348	CcSEcCtD
Nilotinib—Pain—Docetaxel—stomach cancer	4.28e-05	0.000348	CcSEcCtD
Nilotinib—Constipation—Docetaxel—stomach cancer	4.28e-05	0.000348	CcSEcCtD
Nilotinib—Back pain—Methotrexate—stomach cancer	4.27e-05	0.000347	CcSEcCtD
Nilotinib—Dyspepsia—Capecitabine—stomach cancer	4.26e-05	0.000346	CcSEcCtD
Nilotinib—Chills—Epirubicin—stomach cancer	4.26e-05	0.000346	CcSEcCtD
Nilotinib—Arrhythmia—Epirubicin—stomach cancer	4.24e-05	0.000345	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—stomach cancer	4.23e-05	0.000344	CcSEcCtD
Nilotinib—Decreased appetite—Capecitabine—stomach cancer	4.21e-05	0.000342	CcSEcCtD
Nilotinib—Alopecia—Epirubicin—stomach cancer	4.19e-05	0.000341	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Capecitabine—stomach cancer	4.18e-05	0.00034	CcSEcCtD
Nilotinib—Fatigue—Capecitabine—stomach cancer	4.17e-05	0.000339	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—stomach cancer	4.16e-05	0.000338	CcSEcCtD
Nilotinib—Mental disorder—Epirubicin—stomach cancer	4.16e-05	0.000338	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—stomach cancer	4.15e-05	0.000338	CcSEcCtD
Nilotinib—Constipation—Capecitabine—stomach cancer	4.14e-05	0.000336	CcSEcCtD
Nilotinib—Pain—Capecitabine—stomach cancer	4.14e-05	0.000336	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—stomach cancer	4.13e-05	0.000336	CcSEcCtD
Nilotinib—Erythema—Epirubicin—stomach cancer	4.13e-05	0.000336	CcSEcCtD
Nilotinib—Feeling abnormal—Docetaxel—stomach cancer	4.12e-05	0.000335	CcSEcCtD
Nilotinib—Nausea—Fluorouracil—stomach cancer	4.11e-05	0.000334	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—stomach cancer	4.1e-05	0.000334	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—stomach cancer	4.1e-05	0.000333	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—stomach cancer	4.09e-05	0.000333	CcSEcCtD
Nilotinib—Gastrointestinal pain—Docetaxel—stomach cancer	4.09e-05	0.000332	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—stomach cancer	4.08e-05	0.000332	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—stomach cancer	4.08e-05	0.000331	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—stomach cancer	4.08e-05	0.000331	CcSEcCtD
Nilotinib—Flatulence—Epirubicin—stomach cancer	4.07e-05	0.000331	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—stomach cancer	4.05e-05	0.000329	CcSEcCtD
Nilotinib—Back pain—Epirubicin—stomach cancer	4e-05	0.000325	CcSEcCtD
Nilotinib—Feeling abnormal—Capecitabine—stomach cancer	3.99e-05	0.000324	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—stomach cancer	3.98e-05	0.000324	CcSEcCtD
Nilotinib—Malaise—Methotrexate—stomach cancer	3.98e-05	0.000324	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—stomach cancer	3.97e-05	0.000323	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—stomach cancer	3.97e-05	0.000322	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—stomach cancer	3.97e-05	0.000322	CcSEcCtD
Nilotinib—Gastrointestinal pain—Capecitabine—stomach cancer	3.96e-05	0.000322	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—stomach cancer	3.96e-05	0.000322	CcSEcCtD
Nilotinib—Abdominal pain—Docetaxel—stomach cancer	3.95e-05	0.000321	CcSEcCtD
Nilotinib—Body temperature increased—Docetaxel—stomach cancer	3.95e-05	0.000321	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—stomach cancer	3.95e-05	0.000321	CcSEcCtD
Nilotinib—Chills—Doxorubicin—stomach cancer	3.94e-05	0.00032	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—stomach cancer	3.92e-05	0.000319	CcSEcCtD
Nilotinib—Vision blurred—Epirubicin—stomach cancer	3.89e-05	0.000317	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—stomach cancer	3.88e-05	0.000315	CcSEcCtD
Nilotinib—Cough—Methotrexate—stomach cancer	3.85e-05	0.000313	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—stomach cancer	3.85e-05	0.000313	CcSEcCtD
Nilotinib—Urticaria—Capecitabine—stomach cancer	3.85e-05	0.000313	CcSEcCtD
Nilotinib—Ill-defined disorder—Epirubicin—stomach cancer	3.83e-05	0.000312	CcSEcCtD
Nilotinib—Abdominal pain—Capecitabine—stomach cancer	3.83e-05	0.000311	CcSEcCtD
Nilotinib—Body temperature increased—Capecitabine—stomach cancer	3.83e-05	0.000311	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—stomach cancer	3.82e-05	0.000311	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—stomach cancer	3.82e-05	0.000311	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—stomach cancer	3.82e-05	0.00031	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—stomach cancer	3.77e-05	0.000306	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—stomach cancer	3.76e-05	0.000306	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—stomach cancer	3.76e-05	0.000306	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—stomach cancer	3.76e-05	0.000306	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—stomach cancer	3.74e-05	0.000304	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	3.73e-05	0.000303	CcSEcCtD
Nilotinib—Malaise—Epirubicin—stomach cancer	3.73e-05	0.000303	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—stomach cancer	3.71e-05	0.000302	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—stomach cancer	3.71e-05	0.000302	CcSEcCtD
Nilotinib—Syncope—Epirubicin—stomach cancer	3.71e-05	0.000301	CcSEcCtD
Nilotinib—Leukopenia—Epirubicin—stomach cancer	3.7e-05	0.000301	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—stomach cancer	3.7e-05	0.000301	CcSEcCtD
Nilotinib—Hypersensitivity—Docetaxel—stomach cancer	3.68e-05	0.000299	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—stomach cancer	3.68e-05	0.000299	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—stomach cancer	3.65e-05	0.000297	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—stomach cancer	3.63e-05	0.000295	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—stomach cancer	3.63e-05	0.000295	CcSEcCtD
Nilotinib—Cough—Epirubicin—stomach cancer	3.61e-05	0.000293	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—stomach cancer	3.6e-05	0.000293	CcSEcCtD
Nilotinib—Asthenia—Docetaxel—stomach cancer	3.59e-05	0.000292	CcSEcCtD
Nilotinib—Infection—Methotrexate—stomach cancer	3.58e-05	0.000291	CcSEcCtD
Nilotinib—ABCB1—lymph node—stomach cancer	3.57e-05	0.000449	CbGeAlD
Nilotinib—Hypertension—Epirubicin—stomach cancer	3.57e-05	0.00029	CcSEcCtD
Nilotinib—Hypersensitivity—Capecitabine—stomach cancer	3.57e-05	0.00029	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—stomach cancer	3.55e-05	0.000288	CcSEcCtD
Nilotinib—Pruritus—Docetaxel—stomach cancer	3.54e-05	0.000288	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—stomach cancer	3.53e-05	0.000287	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—stomach cancer	3.53e-05	0.000287	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—stomach cancer	3.53e-05	0.000287	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—stomach cancer	3.52e-05	0.000286	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—stomach cancer	3.52e-05	0.000286	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—stomach cancer	3.52e-05	0.000286	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—stomach cancer	3.51e-05	0.000285	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—stomach cancer	3.5e-05	0.000284	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	3.49e-05	0.000284	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—stomach cancer	3.48e-05	0.000283	CcSEcCtD
Nilotinib—Discomfort—Epirubicin—stomach cancer	3.48e-05	0.000283	CcSEcCtD
Nilotinib—Asthenia—Capecitabine—stomach cancer	3.47e-05	0.000282	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—stomach cancer	3.45e-05	0.00028	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—stomach cancer	3.44e-05	0.00028	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—stomach cancer	3.44e-05	0.000279	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—stomach cancer	3.43e-05	0.000279	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—stomach cancer	3.43e-05	0.000279	CcSEcCtD
Nilotinib—Pruritus—Capecitabine—stomach cancer	3.42e-05	0.000278	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—stomach cancer	3.42e-05	0.000278	CcSEcCtD
Nilotinib—Diarrhoea—Docetaxel—stomach cancer	3.42e-05	0.000278	CcSEcCtD
Nilotinib—Confusional state—Epirubicin—stomach cancer	3.4e-05	0.000276	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—stomach cancer	3.38e-05	0.000275	CcSEcCtD
Nilotinib—Oedema—Epirubicin—stomach cancer	3.37e-05	0.000274	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—stomach cancer	3.37e-05	0.000274	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—stomach cancer	3.36e-05	0.000273	CcSEcCtD
Nilotinib—Infection—Epirubicin—stomach cancer	3.35e-05	0.000272	CcSEcCtD
Nilotinib—Cough—Doxorubicin—stomach cancer	3.34e-05	0.000271	CcSEcCtD
Nilotinib—Shock—Epirubicin—stomach cancer	3.32e-05	0.00027	CcSEcCtD
Nilotinib—Diarrhoea—Capecitabine—stomach cancer	3.31e-05	0.000269	CcSEcCtD
Nilotinib—Nervous system disorder—Epirubicin—stomach cancer	3.31e-05	0.000269	CcSEcCtD
Nilotinib—Dizziness—Docetaxel—stomach cancer	3.31e-05	0.000269	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—stomach cancer	3.3e-05	0.000268	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—stomach cancer	3.3e-05	0.000268	CcSEcCtD
Nilotinib—Tachycardia—Epirubicin—stomach cancer	3.29e-05	0.000268	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—stomach cancer	3.28e-05	0.000267	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—stomach cancer	3.28e-05	0.000266	CcSEcCtD
Nilotinib—Hyperhidrosis—Epirubicin—stomach cancer	3.26e-05	0.000265	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—stomach cancer	3.26e-05	0.000265	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—stomach cancer	3.26e-05	0.000265	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—stomach cancer	3.26e-05	0.000265	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—stomach cancer	3.26e-05	0.000265	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—stomach cancer	3.24e-05	0.000264	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—stomach cancer	3.24e-05	0.000263	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	3.23e-05	0.000263	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—stomach cancer	3.22e-05	0.000261	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—stomach cancer	3.21e-05	0.000261	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—stomach cancer	3.21e-05	0.000261	CcSEcCtD
Nilotinib—Dizziness—Capecitabine—stomach cancer	3.2e-05	0.00026	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—stomach cancer	3.18e-05	0.000259	CcSEcCtD
Nilotinib—Vomiting—Docetaxel—stomach cancer	3.18e-05	0.000258	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—stomach cancer	3.17e-05	0.000258	CcSEcCtD
Nilotinib—Rash—Docetaxel—stomach cancer	3.15e-05	0.000256	CcSEcCtD
Nilotinib—Hypotension—Epirubicin—stomach cancer	3.15e-05	0.000256	CcSEcCtD
Nilotinib—Dermatitis—Docetaxel—stomach cancer	3.15e-05	0.000256	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—stomach cancer	3.15e-05	0.000256	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—stomach cancer	3.13e-05	0.000255	CcSEcCtD
Nilotinib—Headache—Docetaxel—stomach cancer	3.13e-05	0.000255	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—stomach cancer	3.12e-05	0.000254	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—stomach cancer	3.11e-05	0.000253	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—stomach cancer	3.11e-05	0.000253	CcSEcCtD
Nilotinib—Infection—Doxorubicin—stomach cancer	3.1e-05	0.000252	CcSEcCtD
Nilotinib—Pain—Methotrexate—stomach cancer	3.08e-05	0.00025	CcSEcCtD
Nilotinib—Vomiting—Capecitabine—stomach cancer	3.08e-05	0.00025	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—stomach cancer	3.07e-05	0.00025	CcSEcCtD
Nilotinib—Shock—Doxorubicin—stomach cancer	3.07e-05	0.00025	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—stomach cancer	3.06e-05	0.000249	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—stomach cancer	3.06e-05	0.000248	CcSEcCtD
Nilotinib—Rash—Capecitabine—stomach cancer	3.05e-05	0.000248	CcSEcCtD
Nilotinib—Insomnia—Epirubicin—stomach cancer	3.05e-05	0.000248	CcSEcCtD
Nilotinib—Dermatitis—Capecitabine—stomach cancer	3.05e-05	0.000248	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—stomach cancer	3.05e-05	0.000248	CcSEcCtD
Nilotinib—Headache—Capecitabine—stomach cancer	3.03e-05	0.000246	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—stomach cancer	3.03e-05	0.000246	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—stomach cancer	3.03e-05	0.000246	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—stomach cancer	3.02e-05	0.000245	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—stomach cancer	3.01e-05	0.000244	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—stomach cancer	2.97e-05	0.000242	CcSEcCtD
Nilotinib—Nausea—Docetaxel—stomach cancer	2.97e-05	0.000241	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—stomach cancer	2.97e-05	0.000241	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—stomach cancer	2.97e-05	0.000241	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—stomach cancer	2.95e-05	0.00024	CcSEcCtD
Nilotinib—Decreased appetite—Epirubicin—stomach cancer	2.93e-05	0.000238	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—stomach cancer	2.92e-05	0.000237	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—stomach cancer	2.91e-05	0.000237	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—stomach cancer	2.91e-05	0.000236	CcSEcCtD
Nilotinib—Pain—Epirubicin—stomach cancer	2.88e-05	0.000234	CcSEcCtD
Nilotinib—Constipation—Epirubicin—stomach cancer	2.88e-05	0.000234	CcSEcCtD
Nilotinib—Nausea—Capecitabine—stomach cancer	2.88e-05	0.000234	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—stomach cancer	2.86e-05	0.000233	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—stomach cancer	2.85e-05	0.000232	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—stomach cancer	2.85e-05	0.000232	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—stomach cancer	2.84e-05	0.000231	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—stomach cancer	2.82e-05	0.000229	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—stomach cancer	2.8e-05	0.000228	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—stomach cancer	2.78e-05	0.000226	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—stomach cancer	2.78e-05	0.000226	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—stomach cancer	2.76e-05	0.000224	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—stomach cancer	2.75e-05	0.000223	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—stomach cancer	2.71e-05	0.00022	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—stomach cancer	2.69e-05	0.000219	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—stomach cancer	2.69e-05	0.000219	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—stomach cancer	2.68e-05	0.000218	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—stomach cancer	2.67e-05	0.000217	CcSEcCtD
Nilotinib—Pain—Doxorubicin—stomach cancer	2.67e-05	0.000217	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—stomach cancer	2.67e-05	0.000217	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—stomach cancer	2.67e-05	0.000217	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—stomach cancer	2.65e-05	0.000216	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—stomach cancer	2.59e-05	0.00021	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—stomach cancer	2.57e-05	0.000209	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—stomach cancer	2.55e-05	0.000207	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—stomach cancer	2.55e-05	0.000207	CcSEcCtD
Nilotinib—Hypersensitivity—Epirubicin—stomach cancer	2.48e-05	0.000202	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—stomach cancer	2.48e-05	0.000201	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—stomach cancer	2.47e-05	0.0002	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—stomach cancer	2.47e-05	0.0002	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—stomach cancer	2.47e-05	0.0002	CcSEcCtD
Nilotinib—Asthenia—Epirubicin—stomach cancer	2.42e-05	0.000197	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—stomach cancer	2.39e-05	0.000194	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—stomach cancer	2.38e-05	0.000194	CcSEcCtD
Nilotinib—Diarrhoea—Epirubicin—stomach cancer	2.31e-05	0.000188	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—stomach cancer	2.3e-05	0.000187	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—stomach cancer	2.29e-05	0.000186	CcSEcCtD
Nilotinib—Rash—Methotrexate—stomach cancer	2.27e-05	0.000185	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—stomach cancer	2.27e-05	0.000185	CcSEcCtD
Nilotinib—Headache—Methotrexate—stomach cancer	2.26e-05	0.000183	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—stomach cancer	2.24e-05	0.000182	CcSEcCtD
Nilotinib—Dizziness—Epirubicin—stomach cancer	2.23e-05	0.000181	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—stomach cancer	2.21e-05	0.000179	CcSEcCtD
Nilotinib—Vomiting—Epirubicin—stomach cancer	2.14e-05	0.000174	CcSEcCtD
Nilotinib—Nausea—Methotrexate—stomach cancer	2.14e-05	0.000174	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—stomach cancer	2.13e-05	0.000174	CcSEcCtD
Nilotinib—Rash—Epirubicin—stomach cancer	2.13e-05	0.000173	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—stomach cancer	2.12e-05	0.000173	CcSEcCtD
Nilotinib—Headache—Epirubicin—stomach cancer	2.11e-05	0.000172	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—stomach cancer	2.06e-05	0.000168	CcSEcCtD
Nilotinib—Nausea—Epirubicin—stomach cancer	2e-05	0.000163	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—stomach cancer	1.98e-05	0.000161	CcSEcCtD
Nilotinib—Rash—Doxorubicin—stomach cancer	1.97e-05	0.00016	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—stomach cancer	1.97e-05	0.00016	CcSEcCtD
Nilotinib—Headache—Doxorubicin—stomach cancer	1.95e-05	0.000159	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—stomach cancer	1.85e-05	0.000151	CcSEcCtD
Nilotinib—CYP2B6—Metabolism—APOA1—stomach cancer	8.59e-07	5.56e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6R—stomach cancer	8.57e-07	5.55e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—stomach cancer	8.53e-07	5.53e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—DPYD—stomach cancer	8.52e-07	5.52e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PIK3CA—stomach cancer	8.52e-07	5.52e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—stomach cancer	8.5e-07	5.51e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—stomach cancer	8.48e-07	5.5e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTP1—stomach cancer	8.47e-07	5.49e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1A—stomach cancer	8.47e-07	5.49e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—stomach cancer	8.47e-07	5.49e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK3—stomach cancer	8.46e-07	5.48e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—stomach cancer	8.45e-07	5.48e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ERCC2—stomach cancer	8.4e-07	5.45e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KRAS—stomach cancer	8.4e-07	5.44e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK3—stomach cancer	8.38e-07	5.43e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HMOX1—stomach cancer	8.36e-07	5.41e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KRAS—stomach cancer	8.35e-07	5.41e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PIK3CA—stomach cancer	8.34e-07	5.4e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—stomach cancer	8.32e-07	5.39e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PIK3CA—stomach cancer	8.31e-07	5.38e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—stomach cancer	8.29e-07	5.37e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB2—stomach cancer	8.29e-07	5.37e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1B—stomach cancer	8.27e-07	5.36e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK8—stomach cancer	8.27e-07	5.36e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—stomach cancer	8.23e-07	5.33e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—stomach cancer	8.17e-07	5.29e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—stomach cancer	8.15e-07	5.28e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPP2R1A—stomach cancer	8.14e-07	5.27e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—PIK3CA—stomach cancer	8.14e-07	5.27e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—stomach cancer	8.12e-07	5.26e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—stomach cancer	8.11e-07	5.26e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PIK3CA—stomach cancer	8.1e-07	5.25e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1B—stomach cancer	8.1e-07	5.25e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK3—stomach cancer	8.08e-07	5.23e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPP2R1A—stomach cancer	8.07e-07	5.23e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—stomach cancer	8.07e-07	5.23e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—stomach cancer	8.07e-07	5.23e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK1—stomach cancer	8.05e-07	5.22e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—stomach cancer	8.05e-07	5.22e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SERPINE1—stomach cancer	8.03e-07	5.2e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—stomach cancer	7.99e-07	5.18e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTP1—stomach cancer	7.99e-07	5.17e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK1—stomach cancer	7.98e-07	5.17e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—stomach cancer	7.98e-07	5.17e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—stomach cancer	7.97e-07	5.16e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTP1—stomach cancer	7.92e-07	5.13e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—stomach cancer	7.9e-07	5.12e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—stomach cancer	7.89e-07	5.11e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—stomach cancer	7.88e-07	5.11e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TYMS—stomach cancer	7.88e-07	5.1e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HMOX1—stomach cancer	7.88e-07	5.1e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—JUN—stomach cancer	7.87e-07	5.1e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—stomach cancer	7.86e-07	5.09e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HMOX1—stomach cancer	7.81e-07	5.06e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—stomach cancer	7.81e-07	5.06e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTM1—stomach cancer	7.79e-07	5.05e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—stomach cancer	7.77e-07	5.03e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RHOA—stomach cancer	7.74e-07	5.02e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—stomach cancer	7.73e-07	5.01e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—stomach cancer	7.71e-07	5e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—stomach cancer	7.71e-07	5e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—JUN—stomach cancer	7.71e-07	5e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—stomach cancer	7.69e-07	4.98e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK1—stomach cancer	7.69e-07	4.98e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—stomach cancer	7.68e-07	4.98e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1B—stomach cancer	7.68e-07	4.97e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—stomach cancer	7.67e-07	4.97e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—stomach cancer	7.66e-07	4.97e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—stomach cancer	7.66e-07	4.96e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—stomach cancer	7.64e-07	4.95e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1A—stomach cancer	7.63e-07	4.95e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK3—stomach cancer	7.63e-07	4.94e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—stomach cancer	7.61e-07	4.93e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—stomach cancer	7.57e-07	4.9e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—stomach cancer	7.56e-07	4.9e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—stomach cancer	7.54e-07	4.89e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—stomach cancer	7.53e-07	4.88e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTT1—stomach cancer	7.53e-07	4.88e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—stomach cancer	7.53e-07	4.88e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—stomach cancer	7.5e-07	4.86e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—stomach cancer	7.49e-07	4.86e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1A—stomach cancer	7.47e-07	4.84e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK3—stomach cancer	7.46e-07	4.83e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK8—stomach cancer	7.45e-07	4.83e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2A6—stomach cancer	7.45e-07	4.82e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TYMS—stomach cancer	7.42e-07	4.81e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—stomach cancer	7.42e-07	4.81e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—stomach cancer	7.38e-07	4.78e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TYMS—stomach cancer	7.36e-07	4.77e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—stomach cancer	7.36e-07	4.77e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—stomach cancer	7.34e-07	4.75e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—stomach cancer	7.32e-07	4.75e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ERCC2—stomach cancer	7.32e-07	4.74e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JUN—stomach cancer	7.31e-07	4.74e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK8—stomach cancer	7.29e-07	4.73e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CAV1—stomach cancer	7.29e-07	4.72e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—stomach cancer	7.27e-07	4.71e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOA1—stomach cancer	7.27e-07	4.71e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK1—stomach cancer	7.26e-07	4.7e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—stomach cancer	7.26e-07	4.7e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—stomach cancer	7.26e-07	4.7e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—stomach cancer	7.25e-07	4.7e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKR1C3—stomach cancer	7.24e-07	4.69e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK3—stomach cancer	7.22e-07	4.68e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—stomach cancer	7.21e-07	4.67e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—stomach cancer	7.17e-07	4.65e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—stomach cancer	7.17e-07	4.64e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—stomach cancer	7.14e-07	4.62e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—stomach cancer	7.11e-07	4.61e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—stomach cancer	7.1e-07	4.6e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK1—stomach cancer	7.1e-07	4.6e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—stomach cancer	7.09e-07	4.6e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1A—stomach cancer	7.09e-07	4.59e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO1—stomach cancer	7.06e-07	4.57e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—stomach cancer	7.03e-07	4.55e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—stomach cancer	6.99e-07	4.53e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	6.96e-07	4.51e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—stomach cancer	6.92e-07	4.49e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK8—stomach cancer	6.92e-07	4.48e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ERCC2—stomach cancer	6.9e-07	4.47e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—stomach cancer	6.88e-07	4.46e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—stomach cancer	6.88e-07	4.46e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK1—stomach cancer	6.87e-07	4.45e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—stomach cancer	6.87e-07	4.45e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—stomach cancer	6.86e-07	4.44e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ERCC2—stomach cancer	6.84e-07	4.43e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—stomach cancer	6.83e-07	4.43e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—stomach cancer	6.81e-07	4.41e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—stomach cancer	6.8e-07	4.41e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—stomach cancer	6.8e-07	4.4e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—stomach cancer	6.79e-07	4.4e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—stomach cancer	6.76e-07	4.38e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—stomach cancer	6.74e-07	4.36e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—stomach cancer	6.7e-07	4.34e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—stomach cancer	6.7e-07	4.34e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—stomach cancer	6.67e-07	4.32e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—stomach cancer	6.67e-07	4.32e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1B—stomach cancer	6.64e-07	4.3e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—stomach cancer	6.51e-07	4.22e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK3—stomach cancer	6.51e-07	4.22e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—stomach cancer	6.49e-07	4.21e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—stomach cancer	6.49e-07	4.2e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—stomach cancer	6.46e-07	4.19e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—stomach cancer	6.43e-07	4.17e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—stomach cancer	6.41e-07	4.15e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—stomach cancer	6.4e-07	4.15e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—stomach cancer	6.39e-07	4.14e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK3—stomach cancer	6.37e-07	4.13e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAV1—stomach cancer	6.35e-07	4.11e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOA1—stomach cancer	6.33e-07	4.1e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—stomach cancer	6.33e-07	4.1e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—stomach cancer	6.33e-07	4.1e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—stomach cancer	6.32e-07	4.1e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JUN—stomach cancer	6.32e-07	4.09e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—stomach cancer	6.3e-07	4.08e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CD44—stomach cancer	6.26e-07	4.06e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—stomach cancer	6.2e-07	4.02e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK1—stomach cancer	6.19e-07	4.01e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—stomach cancer	6.19e-07	4.01e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—stomach cancer	6.19e-07	4.01e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—stomach cancer	6.17e-07	4e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—stomach cancer	6.16e-07	3.99e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—stomach cancer	6.15e-07	3.98e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—stomach cancer	6.13e-07	3.97e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1A—stomach cancer	6.13e-07	3.97e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—stomach cancer	6.1e-07	3.95e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK1—stomach cancer	6.06e-07	3.93e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—stomach cancer	6.06e-07	3.93e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK3—stomach cancer	6.04e-07	3.91e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAV1—stomach cancer	5.98e-07	3.88e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK8—stomach cancer	5.98e-07	3.87e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOA1—stomach cancer	5.97e-07	3.87e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—stomach cancer	5.96e-07	3.86e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—stomach cancer	5.95e-07	3.86e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAV1—stomach cancer	5.93e-07	3.84e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOA1—stomach cancer	5.92e-07	3.83e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—stomach cancer	5.91e-07	3.83e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—stomach cancer	5.89e-07	3.81e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—stomach cancer	5.87e-07	3.81e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—stomach cancer	5.85e-07	3.79e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—stomach cancer	5.83e-07	3.78e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—stomach cancer	5.77e-07	3.74e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—stomach cancer	5.76e-07	3.73e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK1—stomach cancer	5.75e-07	3.72e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—stomach cancer	5.75e-07	3.72e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—stomach cancer	5.73e-07	3.71e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—stomach cancer	5.7e-07	3.69e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	5.67e-07	3.67e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—stomach cancer	5.58e-07	3.62e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—stomach cancer	5.58e-07	3.62e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—stomach cancer	5.52e-07	3.58e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—stomach cancer	5.52e-07	3.58e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—stomach cancer	5.51e-07	3.57e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—stomach cancer	5.47e-07	3.54e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—stomach cancer	5.45e-07	3.53e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—stomach cancer	5.43e-07	3.52e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—stomach cancer	5.37e-07	3.48e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	5.32e-07	3.45e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—stomach cancer	5.28e-07	3.42e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—stomach cancer	5.26e-07	3.41e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—stomach cancer	5.26e-07	3.41e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK3—stomach cancer	5.22e-07	3.38e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—stomach cancer	5.22e-07	3.38e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—stomach cancer	5.21e-07	3.38e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—stomach cancer	5.2e-07	3.37e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMOX1—stomach cancer	5.15e-07	3.34e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—stomach cancer	5.09e-07	3.3e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—stomach cancer	5.08e-07	3.29e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—stomach cancer	5.04e-07	3.27e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—stomach cancer	5.02e-07	3.25e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—stomach cancer	5e-07	3.24e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—stomach cancer	4.99e-07	3.23e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—stomach cancer	4.97e-07	3.22e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK1—stomach cancer	4.97e-07	3.22e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—stomach cancer	4.97e-07	3.22e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—stomach cancer	4.87e-07	3.15e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TYMS—stomach cancer	4.85e-07	3.14e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—stomach cancer	4.82e-07	3.13e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—stomach cancer	4.8e-07	3.11e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—stomach cancer	4.8e-07	3.11e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—stomach cancer	4.76e-07	3.08e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—stomach cancer	4.73e-07	3.06e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—stomach cancer	4.69e-07	3.04e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—stomach cancer	4.69e-07	3.04e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—stomach cancer	4.66e-07	3.02e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—stomach cancer	4.61e-07	2.99e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—stomach cancer	4.52e-07	2.93e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ERCC2—stomach cancer	4.51e-07	2.92e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—stomach cancer	4.48e-07	2.91e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—stomach cancer	4.42e-07	2.86e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—stomach cancer	4.39e-07	2.84e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—stomach cancer	4.31e-07	2.79e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—stomach cancer	4.24e-07	2.75e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—stomach cancer	4.17e-07	2.7e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—stomach cancer	4.14e-07	2.68e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—stomach cancer	4.1e-07	2.66e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—stomach cancer	3.99e-07	2.58e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAV1—stomach cancer	3.91e-07	2.53e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOA1—stomach cancer	3.9e-07	2.53e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—stomach cancer	3.82e-07	2.47e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—stomach cancer	3.66e-07	2.37e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—stomach cancer	3.44e-07	2.23e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—stomach cancer	3.1e-07	2.01e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—stomach cancer	3.09e-07	2e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—stomach cancer	2.96e-07	1.92e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—stomach cancer	2.7e-07	1.75e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—stomach cancer	2.7e-07	1.75e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—stomach cancer	2.55e-07	1.65e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—stomach cancer	2.52e-07	1.63e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—stomach cancer	1.66e-07	1.08e-06	CbGpPWpGaD
